AEON Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AEON Biopharma, Inc. (AEON) on April 22, 2025. The Company is incorporated in Delaware and its Class A Common Stock trades on the NYSE American under the symbol "AEON". The report addresses the status of the Company's compliance with NYSE American continued listing standards.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory listing status and does not contain financial performance data.
Material Changes and Listing Status
- Non-Compliance Notice: The Company previously received notice of non-compliance with NYSE American Sections 1003(a)(i), (ii), and (iii) of the Company Guide.
- Plan Acceptance: On April 22, 2025, the NYSE American accepted the Company's plan to regain compliance.
- Compliance Deadline: The Company has been granted a Plan Period extending until August 3, 2026, to meet the required listing standards.
- Trading Status: The Common Stock will continue to be listed and traded on the NYSE American during the Plan Period, subject to other listing requirements.
Outlook, Risks, and Management Commentary
Management intends to take all reasonable measures to regain compliance by the August 3, 2026 deadline. The Company will be subject to periodic reviews by the NYSE American regarding its progress. The primary risk identified is that if the Company fails to regain compliance by the deadline or fails to make sufficient progress consistent with the Plan, the NYSE American may initiate delisting proceedings. The filing states that the acceptance of the plan has no immediate impact on ongoing business operations or SEC reporting requirements.
Key Facts for Investor Verification
- Verify the specific financial metrics (e.g., stock price, market cap, working capital) that caused the initial non-compliance with Sections 1003(a)(i), (ii), and (iii).
- Monitor periodic progress reports from the Company regarding the initiatives outlined in the accepted Plan.
- Confirm the August 3, 2026 deadline for regaining full compliance to avoid potential delisting.
- Review the February 7, 2025 Form 8-K for the original details of the non-compliance notice.